Aura Biosciences, Inc. (NasdaqGM: AURA)
Health Care · Biotechnology · US
$7.73
-1.15% today · +20.0% 1Y
Aura Biosciences, Inc. (NasdaqGM: AURA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $801.64M and employs 113 people.
Over the last twelve months the share price has gained 20.0%, trading between 4.73 and 9.54.
Tweenvest scores Aura Biosciences, Inc. across four factors: quality 26/100. Its strongest factor is quality.
AURA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $801.64M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.77
- Dividend yield
- —
- Beta (5Y)
- 0.40
- 52-week high
- $9.54
- 52-week low
- $4.73
- Avg volume (3M)
- —
- Shares outstanding
- 103.70M
- Employees
- 113
- Next earnings
- —
About Aura Biosciences, Inc.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
- ISIN
- US05153U1079
- Founded
- 2009
- Listed since
- Oct 29, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.